Literature DB >> 11805230

Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain.

Shao-Rui Chen1, Krystyna M Wozniak, Barbara S Slusher, Hui-Lin Pan.   

Abstract

Increased glutamate availability in the spinal cord and primary afferent nerves plays an important role in acute and chronic pain. Afferent ectopic discharges from the site of nerve injury constitute a source of abnormal sensory input to the spinal dorsal horn. The ectopic afferent activity is largely responsible for the development of hypersensitivity of dorsal horn neurons and neuropathic pain. Inhibition of glutamate carboxypeptidase II (GCP II) reduces glutamate release generated from N-acetyl-aspartyl-glutamate in nerve tissues and may have an analgesic effect on neuropathic pain. In the present study, we determined the effect of a GCP II inhibitor, 2-(phosphono-methyl)-pentanedioic acid (2-PMPA), on allodynia and ectopic afferent discharges in an animal model of neuropathic pain. Neuropathic pain was induced by partial ligation of the left sciatic nerve in rats. Tactile allodynia was assessed using von Frey filaments applied to the plantar surface of the injured hindpaw. Single-unit activity of ectopic discharges was recorded from the sciatic nerve proximal to the site of ligation. Intravenous injection of 50 to 100 mg/kg 2-PMPA significantly reduced allodynia in a dose-dependent manner. Furthermore, 2-PMPA dose-dependently attenuated the ectopic discharge activity of injured sciatic afferent nerves. At a dose of 100 mg/kg, 2-PMPA significantly inhibited the ectopic activity from 14.7 +/- 2.1 to 4.4 +/- 0.5 impulses/s without altering the conduction velocity of afferent nerves. Therefore, these data suggest that the antiallodynic effect of 2-PMPA may be mediated, at least in part, by inhibition of ectopic afferent discharges at the site of nerve injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805230     DOI: 10.1124/jpet.300.2.662

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA).

Authors:  Rana Rais; Camilo Rojas; Krystyna Wozniak; Ying Wu; Ming Zhao; Takashi Tsukamoto; Michelle A Rudek; Barbara S Slusher
Journal:  J Pharm Biomed Anal       Date:  2013-08-30       Impact factor: 3.935

3.  Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity.

Authors:  Anna Plechanovová; Youngjoo Byun; Glenda Alquicer; L'ubica Skultétyová; Petra Mlčochová; Adriana Němcová; Hyung-Joon Kim; Michal Navrátil; Ronnie Mease; Jacek Lubkowski; Martin Pomper; Jan Konvalinka; Lubomír Rulíšek; Cyril Bařinka
Journal:  J Med Chem       Date:  2011-10-11       Impact factor: 7.446

Review 4.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

5.  Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.

Authors:  Jesse Alt; Marigo Stathis; Camilo Rojas; Barbara Slusher
Journal:  FASEB J       Date:  2013-03-23       Impact factor: 5.191

6.  Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism.

Authors:  James J Vornov; Krystyna M Wozniak; Ying Wu; Camilo Rojas; Rana Rais; Barbara S Slusher
Journal:  J Pharmacol Exp Ther       Date:  2013-06-17       Impact factor: 4.030

7.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

Authors:  Jeroen R Mesters; Cyril Barinka; Weixing Li; Takashi Tsukamoto; Pavel Majer; Barbara S Slusher; Jan Konvalinka; Rolf Hilgenfeld
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

8.  Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo.

Authors:  Rana Rais; Randall Hoover; Krystyna Wozniak; Michelle A Rudek; Takashi Tsukamoto; Jesse Alt; Camilo Rojas; Barbara S Slusher
Journal:  Drug Metab Dispos       Date:  2012-09-04       Impact factor: 3.922

9.  Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies.

Authors:  Camilo Rojas; Marigo Stathis; Michael Polydefkis; Michelle A Rudek; Ming Zhao; Gigi J Ebenezer; Barbara S Slusher
Journal:  J Transl Med       Date:  2011-03-09       Impact factor: 5.531

Review 10.  Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders.

Authors:  Michelle C Potter; Mariana Figuera-Losada; Camilo Rojas; Barbara S Slusher
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.